Valye reports for unlimited access

Launch Two Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in May 2024 in the Cayman Islands. It was formed to identify and merge with a target business, primarily in technology sectors related to financial services, real estate, or asset management, though it may consider other industries. The company completed its IPO in October 2024, raising gross proceeds of $237 million, which are held in a trust account to fund the Business Combination. The management team and advisors have significant experience in SPAC transactions and relevant industries. The company has no operating revenues and focuses on identifying a suitable acquisition target within a 24-month period ending October 2026. It offers target companies an alternative to traditional IPOs by providing access to public capital markets through a Business Combination.

Himax Technologies, Inc. was incorporated in 2001 and reorganized in 2005 to establish a Cayman Islands holding company structure for overseas listing. The company is a global leader in fabless semiconductor solutions focused on display imaging processing technologies. Its products include display driver ICs, timing controllers, touch controller ICs, ASIC services, LCoS and MEMS products, power ICs, CMOS image sensors, wafer level optics, 3D sensing, and ultralow power AI sensing technologies. Himax serves multiple industries including TVs, monitors, laptops, mobile phones, tablets, automotive, ePaper, and industrial displays. The company is the global market share leader in automotive display technology and offers advanced integrated solutions such as TDDI and OLED technologies. Himax operates a fabless model, outsourcing wafer fabrication, gold bumping, assembly, and testing to specialized third-party providers while maintaining some internal testing capabilities. The company’s customer base is concentrated, with a few large customers accounting for a significant portion of revenues. Himax’s products are customized to meet specific panel designs and customer requirements, involving close collaboration with customers. The company has a global presence with offices and sales teams in Asia and the USA. Financially, Himax reported $832 million in revenue for the year ended December 31, 2025, with strong liquidity ratios. The company’s ADSs have been listed on NASDAQ since 2006.

Sportradar Group AG operates as a leading global technology platform specializing in sports data and analytics, primarily serving the sports betting industry. Founded in 2001 and headquartered in Switzerland, the company provides mission-critical products and services to three main client groups: betting operators, sports leagues, and media companies. Its offerings include pre-match and live sports data, odds, audiovisual content, managed betting services, iGaming solutions, marketing and advertising tools, integrity services such as fraud monitoring and anti-doping, and broadcasting and digital media solutions. Sportradar’s platform integrates advanced technologies including computer vision, AI, and machine learning to capture, process, and distribute sports data with high accuracy and low latency. The company holds exclusive partnerships with major sports leagues worldwide, enabling access to official data and content rights. Sportradar’s business model emphasizes cross-selling and expanding client usage, supported by a strong customer net retention rate. The company reported €1.29 billion in revenue and €100 million in net income for 2025, with a solid liquidity position and access to credit facilities. Sportradar’s platform is deeply embedded in the sports ecosystem, serving clients in over 120 countries and addressing the full sports betting value chain from data generation to client engagement and risk management [S1].

VirTra, Inc. develops and markets advanced firearms and use-of-force training simulators designed to provide realistic, scenario-based training for law enforcement, military, and commercial clients. The company’s product portfolio includes multi-screen simulators such as the V-300™ and V-180™, single-screen systems like the V-100™ and V-ST PRO™, and the V-XR extended reality headset-based training solution. VirTra’s simulators incorporate patented technologies including the Threat-Fire™ shoot-back system and True-Fire™ recoil kits to enhance training realism and effectiveness. The company also offers software and training programs such as V-VICTA™, Red Dot Optic Training, and a subscription-based equipment partnership program (STEP™). VirTra’s manufacturing and assembly operations are based in Chandler, Arizona, and it sources components from multiple suppliers. The company’s revenues are primarily derived from government contracts, representing about 79% of total revenues in 2025. VirTra invests in research and development to innovate and expand its product offerings, including leveraging artificial intelligence and large language models to improve training realism and reduce development costs.

TechnipFMC plc is a global oilfield services company specializing in subsea and surface technologies. The company generates most of its revenue from long-term contracts involving the design, manufacture, and servicing of products and systems for oil and natural gas exploration and production. It operates across multiple geographic regions including Latin America, Europe and Central Asia, North America, Africa, Asia Pacific, and the Middle East. The company reports contract assets and liabilities reflecting the timing of revenue recognition and billing, with a significant order backlog representing future revenue. Financial disclosures show a solid liquidity position with over $1 billion in cash and cash equivalents and a current ratio above 1. The company also manages contingent liabilities related to guarantees and maintains credit ratings in the investment grade range. Recent quarterly results indicate ongoing profitability and active capital management including share repurchases and dividend payments.

Hoyne Bancorp, Inc. is a recently formed Delaware savings and loan holding company owning Hoyne Savings Bank, an Illinois-chartered bank with a 138-year history serving Cook County and the Chicago metropolitan area. The company completed its stock conversion and offering in December 2025, listing on Nasdaq under ticker HYNE. Hoyne Savings Bank operates six full-service branches and a loan production office, focusing on diversified lending including residential mortgages, commercial real estate, commercial construction, and commercial and industrial loans. The company’s business model centers on banking services in a competitive regional market, with cash flow dependent on investment earnings and dividends from the bank. The company does not own property and shares officers with the bank, leveraging the bank’s support staff.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing elraglusib, a novel GSK-3β inhibitor, targeting high-impact, difficult-to-treat cancers. The company’s lead asset, elraglusib, is being developed in intravenous injection and oral tablet forms, enabling treatment across multiple cancer types including metastatic pancreatic ductal adenocarcinoma (mPDAC), pediatric cancers such as Ewing sarcoma and neuroblastoma, and other refractory cancers. The company has treated over 500 patients in clinical trials and has reported positive Phase 2 data showing statistically significant survival benefits in mPDAC. The oral tablet formulation is planned for Phase 1/2 trials in refractory cancers subject to funding. Actuate Therapeutics operates with a small team and outsources manufacturing and clinical development activities. The company holds orphan drug and fast track designations for pancreatic and other cancers. Financially, the company reported a net loss and holds cash reserves sufficient for near-term operations but requires additional funding to continue development and commercialization efforts.

Iris Acquisition Corp II is a special purpose acquisition company (SPAC) formed to identify and merge with one or more businesses, primarily targeting mid-market companies with meaningful revenue and growth potential. The company operates with a generalist investment approach but prioritizes sectors where it has domain expertise, including technology, business services, consumer products, and industrial technologies. The management team is globally experienced and based in Dubai, leveraging extensive networks to source potential acquisition targets. The company completed its IPO in early 2026 and has a 24-month window to complete a business combination. It has signed a letter of intent to form Freedom Metals Corporation, focusing on strategic antimony and tungsten assets in the U.S.

FB Bancorp, Inc. is a financial services holding company with a bank subsidiary named Fidelity Bank located in New Orleans, Louisiana. The company engages in banking operations and recently divested certain assets of its NOLA mortgage division to First Federal Bank. The asset sale included tangible property, prepaid expenses, and intellectual property, and was completed in early 2026. Financial disclosures indicate modest revenue and profitability for the fiscal year 2025, with a strong cash position. The company is publicly traded on the Nasdaq under the ticker FBLA. Public disclosures do not provide detailed information on the company's full business model, sector classification, or product lines beyond the banking subsidiary and asset sale.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class oral WEE1 inhibitor designed to treat ovarian cancer and other tumor types. The company is focused on Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib has shown anti-tumor activity and a manageable safety profile in clinical trials. The DENALI clinical trial program includes multiple phases, with Part 2a enrollment completed and a topline readout anticipated by year-end 2026. A Phase 3 confirmatory trial (ASPENOVA) is planned to support full regulatory approval. Zentalis also explores combination therapies and additional indications as resources allow. The company does not own manufacturing facilities and relies on third-party contract manufacturers. Financially, Zentalis has incurred significant net losses and has no approved products or revenue from sales to date. As of December 31, 2025, it held approximately $36 million in cash and cash equivalents and $209.9 million in marketable securities, with liquidity ratios indicating sufficient funds into late 2027. The company faces competition from other WEE1 inhibitors in development and operates in a highly competitive and regulated industry.

Cantor Equity Partners IV, Inc. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in 2021. It completed an IPO in August 2025, raising $450 million plus $9 million in a private placement, with proceeds held in a Trust Account invested in U.S. government securities or money market funds. The company’s business model is to identify and acquire a target company primarily in financial services, digital assets, healthcare, real estate services, technology, or software sectors. The management team and Sponsor are affiliates of Cantor, a diversified financial and real estate services company, providing expertise in investment banking, brokerage, and commercial real estate services. The company has until August 22, 2027, to complete a business combination or else will liquidate and redeem public shares. It currently has no employees and only two executive officers who devote time as necessary until the business combination is completed. The company may raise additional funds through equity or debt securities to complete the business combination if needed, which could dilute public shareholders.

CapsoVision develops and commercializes advanced capsule endoscopy systems for diagnosing abnormalities in the gastrointestinal tract. Its flagship product, CapsoCam Plus, is a single-use capsule that captures 360° panoramic video of the small bowel mucosa, enabling superior diagnostic yield compared to traditional end-view capsules. The system includes software platforms CapsoCloud and CapsoView for video review and analysis, supporting telemedicine and remote ingestion. The company is advancing AI-assisted pathology detection technology to enhance diagnostic efficiency and accuracy. CapsoVision is also developing the CapsoCam Colon capsule, designed to visualize the colon and detect polyps using AI and 3D sensing technology. The company sells primarily to gastroenterologists in clinics and hospitals, using a direct sales model in the U.S. and distributors internationally. Manufacturing relies on single-source suppliers in Asia, with assembly completed in the U.S. The company has a history of net losses and requires additional financing to support growth and product development.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing oral delivery technology for biologics and drugs to provide a convenient alternative to injections. Its proprietary platform, the RaniPill capsule, has two configurations: RaniPill GO for microtablet delivery and RaniPill HC for high-capacity liquid payloads. The company is advancing multiple pipeline programs including RT-114 (GLP-1/GLP-2 dual agonist for obesity), RT-116 (semaglutide for obesity), and RT-105 (anti-TNF-alpha antibody for inflammatory diseases). Rani Therapeutics has no approved products or commercial revenue and is pursuing partnerships and collaborations, including a key agreement with Chugai Pharmaceutical. The company employs a vertically integrated manufacturing strategy with plans for automated production lines. Financially, as of December 31, 2025, it held $18.6 million in cash and equivalents, had no outstanding debt, and reported a net loss of $29.7 million for the fiscal year. Recent leadership changes and financing activities have been reported.

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company developing treatments for rare diseases, with a focus on Netherton Syndrome. Its lead product candidate, QRX003, is a topical lotion formulated with a broad-spectrum serine protease inhibitor and proprietary technology. The company has received orphan drug designation in Europe and a Rare Pediatric Disease designation from the FDA for QRX003. It has initiated pivotal clinical trials following FDA clearance and is preparing for a Phase 3 trial. The company has filed patent applications to protect its intellectual property. Quoin Pharmaceuticals has not yet generated revenue and has incurred significant net losses since inception. It maintains liquidity through cash, short-term investments, and recent private placements. The company faces typical risks of clinical-stage biopharmaceutical firms, including regulatory, financial, operational, and competitive challenges.

Worksport Ltd is a company focused on designing, developing, and manufacturing innovative automotive accessories and clean energy products. Its core product lines include soft and hard folding tonneau covers for light trucks, solar-integrated tonneau covers (SOLIS), portable energy storage systems (COR), and advanced heat pump systems developed by its subsidiary Terravis Energy. The company operates manufacturing and assembly facilities in the U.S. and maintains a diversified supplier network to mitigate supply chain risks. Worksport has expanded its dealer network significantly and pursues both business-to-business and direct-to-consumer sales channels. The company has a substantial intellectual property portfolio protecting its innovations and continues to invest in research and development and manufacturing scale-up. Worksport has raised capital through at-the-market offerings and warrant inducements to support its operations and growth initiatives. The company faces competitive pressures in both the tonneau cover and portable power station markets and operates with a history of operating losses and financing reliance.

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for orphan pulmonary and fibrosis indications with limited or no approved treatments. Its lead candidate, LTI-03, is a peptide drug derived from the Cav1 protein, targeting idiopathic pulmonary fibrosis (IPF). LTI-03 has orphan drug designation in the U.S. and EU and has completed Phase 1a and 1b clinical trials demonstrating safety, tolerability, and positive biomarker activity related to fibrosis reduction and epithelial cell protection. The company initiated a Phase 2 RENEW trial in 2025, enrolling IPF patients across multiple countries, with regulatory clearances from FDA, EMA, MHRA, and others. Development of LTI-01, targeting loculated pleural effusion (LPE), is paused indefinitely due to capital limitations. Rein Therapeutics has no approved products or revenues and relies on external funding to support clinical development and operations. The company rebranded from Aileron Therapeutics in January 2025 to focus on pulmonary and fibrosis therapies.

Chaince Digital Holdings Inc. is a Cayman Islands holding company conducting operations primarily through its subsidiaries in the United States, Hong Kong, and China. Historically engaged in blockchain and digital asset mining activities, including Bitcoin and Filecoin mining, the company strategically discontinued all digital asset mining operations in December 2025 to focus on financial services and advisory businesses. The current core operations include financial advisory, capital markets advisory, brokerage-related services, and corporate consulting, delivered mainly through its U.S. subsidiaries Chaince Securities, Inc. and Chaince Securities, LLC (a FINRA-registered broker-dealer and registered investment advisor), and Ucon Capital (HK) Limited. The company serves corporate clients and institutional investors primarily in North America, Greater China, and Southeast Asia. Revenue is project-based and transaction-driven, with a client base of over 20 corporate clients as of the end of 2025. The company completed several private placements in 2025 and early 2026, raising capital through share issuances. As of December 31, 2025, the company held strong liquidity with cash and equivalents of approximately $33.8 million and a current ratio of 25.71, but reported a net loss of about $5.1 million for the year. The company is completing an orderly wind-down of discontinued digital asset mining operations and continues to hold certain digital assets and stablecoins as part of treasury and investment activities. Marketing efforts focus on relationship-driven client acquisition and strategic partnerships, leveraging a global presence. The company operates in a highly competitive financial services industry and faces risks related to limited operating history in its current core business, revenue fluctuations, client concentration, competition, regulatory compliance, and digital asset volatility.

Borr Drilling Ltd operates as an offshore drilling contractor, providing drilling services primarily for the oil and gas industry. Incorporated in Bermuda, the company’s shares trade on the New York Stock Exchange and Euronext Growth Oslo, with plans to up-list on the Oslo Stock Exchange. The company’s business model centers on owning and operating offshore drilling rigs, generating revenue through drilling contracts with energy companies. Borr Drilling’s financial reporting follows U.S. GAAP standards, and it maintains governance policies including insider trading and ethics codes. The company manages market risks such as foreign currency exposure and interest rate fluctuations, with a focus on maintaining liquidity and operational efficiency. Leadership includes CEO Bruno Morand, appointed in 2025 with extensive industry experience. Borr Drilling’s shareholder base includes significant institutional investors and insiders, reflecting active market interest.

Amazon.com, Inc. is a leading global internet retailer and cloud services provider. Its business model includes e-commerce platforms, Amazon Web Services (AWS) cloud computing, and expanding healthcare offerings such as pharmacy services. The company engages in strategic investments and partnerships, notably a significant equity commitment to OpenAI, reflecting a focus on artificial intelligence integration. Amazon's financial position as of the end of 2025 shows strong liquidity and profitability, supported by diversified revenue streams and capital market activities.

Austin Gold Corp. is a foreign private issuer headquartered in Vancouver, Canada, engaged in gold exploration activities primarily in Nevada, United States. The company files annual reports on Form 20-F and periodic reports on Form 6-K with the SEC, providing financial statements and operational updates. Its key projects include Kelly Creek, Stockade Mountain, Lone Mountain, and Fourmile Basin. Financial disclosures indicate the company is in a development stage with no reported revenue but incurs operating losses. The company maintains liquidity through cash and current assets, though detailed liabilities and liquidity ratios are not disclosed.

Global-E Online Ltd. provides an integrated global e-commerce platform designed to simplify international online shopping and selling. The platform localizes the shopper experience by offering native language support, market-adjusted pricing, local payment options, compliance with local regulations including customs duties and taxes, shipping, after-sales support, and returns management. The company generates revenue primarily through service fees based on transaction values processed on its platform and through optional fulfillment services such as shipping and handling. As of December 31, 2025, Global-E served 1,547 merchants across more than 30 countries, with significant geographic diversification in both merchant origin and destination markets. The company has made strategic acquisitions, including ReturnGo Ltd., to enhance its post-purchase solutions and maintains partnerships such as with Shopify for managed international markets. The executive leadership team includes experienced co-founders and senior officers with backgrounds in banking, technology, and global sales.

Kornit Digital Ltd. is an Israeli company incorporated in 2002 and publicly traded on Nasdaq since 2015 under the ticker KRNT. It specializes in digital printing solutions for the printed textile industry, focusing on the rapidly growing direct-to-garment (DTG) and direct-to-fabric segments. The company’s product portfolio includes proprietary digital printing systems, curing systems, inks, consumables, software, and value-added services. Kornit's patented wet-on-wet printing technology eliminates the need for fabric pre-treatment, enabling high-quality printing on a variety of untreated fabrics. The company serves fulfillers and demand generators such as brands and content creators primarily in fashion, apparel, and home décor. Kornit’s business model leverages a growing installed base of systems to drive recurring sales of ink and consumables. In 2024, Kornit introduced the All-Inclusive Click (AIC™) model, offering customers a full solution with fixed price per impression and minimum annual commitments, enhancing revenue predictability. The company employs a hybrid sales model combining direct sales and channel partners globally. Maintenance and support are provided through a mix of internal teams and distributor-employed engineers. Kornit operates in a market characterized by strong growth in digital textile printing, driven by e-commerce expansion, social media influence, and sustainability trends. The company reported $208.2 million in revenue and a net loss of $13.5 million for the year ended December 31, 2025, with a strong liquidity position and ongoing capital expenditures focused on equipment production for lease.

ELTEK LTD, incorporated in 1970 and headquartered in Israel, specializes in manufacturing technologically advanced custom printed circuit boards (PCBs), including rigid, flexible, and flex-rigid types with up to 40 layers. The company targets short run, prototype, pre-production, and low to medium volume production primarily for high-growth advanced electronics applications. Its customer base spans defense and aerospace, medical equipment, industrial equipment, and other sectors, with sales concentrated in Israel and international markets including North America and Europe. ELTEK holds key certifications such as ITAR registration and Nadcap accreditation, supporting its focus on high-reliability applications. The company has invested significantly in production equipment and infrastructure to enhance capacity and technological capabilities. Financially, ELTEK reported $51.79 million in revenues and $0.826 million net income for 2025, with a strong liquidity position and no outstanding bank debt. Marketing and sales efforts include direct personnel and partnerships with distributors and manufacturers globally [S1].

WEN Acquisition Corp is a Cayman Islands exempted blank check company incorporated in January 2025 to effect a business combination with one or more businesses, primarily targeting fintech infrastructure companies focused on digital assets and blockchain integration. The company completed its IPO in May 2025, raising approximately $300 million, which is held in a trust account. The management team, led by CEO Julian M. Sevillano and CFO Jurgen van de Vyver, has extensive experience in fintech, payments, stablecoins, and digital assets, supported by advisors with SPAC expertise. The company has no operating revenues and has not yet selected a business combination target. It must complete a business combination by May 19, 2027, or liquidate and return funds to shareholders. The company’s acquisition criteria emphasize cash flow growth, strong management, public company advantages, and blockchain-based competitive advantages. As of December 31, 2025, the company had strong liquidity with a current ratio of 5.19 and reported net income for the fiscal year, though EPS was negative in Q1 2025. The company announced a trading separation of Class A shares and warrants effective July 7, 2025.

Globa Terra Acquisition Corp is a Cayman Islands exempted blank check company incorporated in October 2024 to effect a merger or similar business combination. It has not commenced operations or generated revenue and focuses on identifying a target business primarily in the agribusiness and water sectors across the Americas. The company completed its IPO in July 2025, raising approximately $175 million, which is held in a trust account invested in U.S. government securities. The company’s strategy includes targeting companies with strong fundamentals, multi-country operations, and ESG integration, aiming to create long-term value through private equity-style operational enhancements. The management team has significant SPAC and public company experience, which supports sourcing and executing transactions.

Churchill Capital Corp XI is a Cayman Islands exempted blank check company (SPAC) incorporated in June 2025. Its purpose is to identify and complete an initial business combination with one or more target companies in any industry. The company completed its IPO in December 2025, issuing 41.4 million units and raising $414 million, which is held in a Trust Account. The management team, led by Michael Klein and supported by M. Klein and Company and Archimedes Advisors LLC, leverages extensive industry and operational experience to source and evaluate acquisition targets. The company has not yet selected a target and has generated no operating revenues. It must complete a business combination by December 18, 2027, or face liquidation and distribution of Trust Account funds to shareholders. The company maintains strong liquidity with a current ratio of 8.13 as of December 31, 2025.

Proem Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2025. It completed its initial public offering in February 2026, issuing units consisting of ordinary shares and redeemable warrants, raising gross proceeds of $130 million plus a private placement. The company has not commenced operations or selected a business combination target as of the latest filing. Its business strategy focuses on acquiring a high-growth, disruptive technology company, leveraging the expertise of its sponsor, Proem Asset Management, a technology-focused investment firm. The company targets sectors including artificial intelligence, blockchain, SaaS, data infrastructure, and cybersecurity. It has a 24-month window from the IPO to complete a business combination, with provisions for shareholder redemptions and potential liquidation if no combination is completed. The company currently generates no operating revenues and holds IPO proceeds in a trust account.

NU RIDE INC., formerly Lordstown Motors Corp., emerged from Chapter 11 bankruptcy in March 2024. Post-emergence, the company’s operations focus on resolving bankruptcy claims, prosecuting ongoing litigation including a significant case against Foxconn, managing retained causes of action, and exploring potential strategic alternatives or business combinations. The company’s assets include cash, short-term investments, loans receivable related to billboard leasehold assets, and net operating loss carryforwards. NU RIDE does not currently generate revenue and operates as a single segment focused on claims administration and litigation management. The company relocated its headquarters to New York, New York, and had one full-time employee as of March 2026.

Southland Holdings, Inc. is a diversified leader in specialty infrastructure construction with a history dating back to 1900. Headquartered in Grapevine, Texas, Southland operates primarily in North America through its two main segments: Civil and Transportation. The Civil segment focuses on water infrastructure projects including pipelines, treatment plants, and tunneling, while the Transportation segment specializes in bridges, roadways, marine facilities, and specialty structures. The company serves a mix of public and private customers, including federal and state agencies, local transit authorities, utilities, and private industrial and commercial owners. Southland emphasizes self-performance to control costs and quality, and has recently exited certain Materials & Paving activities to concentrate on more profitable lines. The company’s contracts are primarily fixed-price and obtained through competitive bidding or direct negotiation. Revenue recognition follows ASC 606 standards. Southland faces seasonal and weather-related variability, competitive pressures, and market risks such as interest rate fluctuations. The company reported $772.2 million in revenue and a net loss of $308.4 million for the year ended December 31, 2025, with liquidity challenges addressed through credit agreement amendments and surety support.

SpyGlass Pharma, Inc. focuses on developing long-acting, sustained drug delivery systems for chronic eye conditions. Its lead candidate, the BIM-IOL System, integrates proprietary drug pads with an intraocular lens implanted during cataract surgery to deliver bimatoprost over three years, targeting patients with open-angle glaucoma or ocular hypertension. The company is conducting Phase 3 clinical trials and plans to submit a New Drug Application following successful trial completion. SpyGlass Pharma has no commercial products or revenues and has historically incurred significant losses. It relies on third-party manufacturers and holds exclusive intellectual property licenses critical to its technology. The company completed its IPO in early 2026 and has attracted multiple analyst coverage initiations with positive recommendations.

GP-Act III Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model is to identify and complete a business combination with one or more target companies. The company completed its IPO in May 2024, raising gross proceeds of approximately $287.5 million. It holds these proceeds in a trust account invested mainly in Treasury securities and money market funds. The company has not commenced any operating activities or generated operating revenues as of June 30, 2025. Its income is derived from interest earned on the trust account. The company has incurred general and administrative expenses related to its formation and IPO activities. It is classified as an emerging growth company and has elected to use the extended transition period for new accounting standards. The company has outstanding Class A and Class B ordinary shares, with Class A shares subject to possible redemption. It has related party loans to finance transaction costs, which are non-interest bearing and payable upon consummation of a business combination or the second anniversary of the IPO.

Seafarer Exploration Corp focuses on rescue archaeology and the archaeologically-sensitive exploration, recovery, and conservation of historic shipwrecks. The company aims to monetize recovered artifacts after conservation and scientific research. It conducts extensive archival research and develops proprietary technology, notably the SeaSearcher, to enhance exploration accuracy and efficiency. The business involves a multi-year, multi-stage process with high uncertainty and significant financial and operational risks. Seafarer holds permits for exploration and recovery at sites such as Juno Beach and Melbourne Beach and has exclusive rights to conduct recovery operations at the Juno Beach wreck site. The company also engages in media initiatives to promote its activities.

DBV Technologies S.A. operates as a biotechnology company specializing in the research and development of epicutaneous immunotherapy products, with a primary focus on the Viaskin Peanut patch for peanut allergy treatment. The company is transitioning from a development-stage to a potential commercial-stage organization, evidenced by recent executive appointments and commercial strategy initiatives. DBV Technologies conducts clinical trials including the Phase 3 VITESSE study and the COMFORT Toddlers study, with recent positive topline results reported. The company has established manufacturing and supply agreements, notably with SANOFI, to support production capacity. Financially, DBV Technologies reported no operating revenue in 2025 aside from a French research tax credit, while incurring significant operating expenses primarily related to research and development, sales and marketing, and general administration. The company raised substantial capital through PIPE and ATM equity offerings, resulting in a strong cash position at the end of 2025. DBV Technologies is preparing for potential regulatory approvals and commercial launch in North America and Europe, with ongoing investments in inventory, manufacturing, and organizational scaling.

Abercrombie & Fitch Co. is a Delaware-incorporated global retailer specializing in apparel, personal care products, and accessories for men, women, and children. The company operates an omnichannel business model, selling primarily through its own stores and digital platforms, supplemented by third-party arrangements. It manages its operations across three geographic segments: Americas, EMEA, and APAC. The company’s brand portfolio includes Abercrombie and Hollister, both targeting customers seeking quality and style. Revenue is recognized upon transfer of control to customers, net of returns and discounts. The company invests in store experiences and digital initiatives to support growth and customer engagement. Segment reporting and financial disclosures provide detailed insights into sales, costs, and operating income by region. The company also maintains a share repurchase program to return capital to shareholders.

Dermata Therapeutics, Inc. is focused on developing and commercializing skincare products addressing common and underserved skin conditions. Initially focused on prescription (Rx) products, Dermata's lead asset was XYNGARI (DMT310), a topical acne treatment studied in Phase 3 clinical trials with positive results announced in March 2025. In September 2025, the company strategically shifted to developing direct-to-consumer (DTC) and business-to-business (B2B) over-the-counter (OTC) skincare products leveraging its proprietary Bioneedle technology derived from Spongilla lacustris, a freshwater sponge. This shift aims to accelerate commercialization, reduce regulatory burden, and lower development costs. Dermata plans to launch its first cosmetic product, a foundational skin renewal treatment, in mid-2026, followed by an OTC acne clearing treatment. The company intends to market products through its website and professional channels including aestheticians and dermatologists, supported by a certification program. Dermata also explores expanding its product portfolio to address other skin conditions such as psoriasis and seborrheic dermatitis. The company maintains an exclusive supply agreement for its Spongilla raw material and is engaged in a license dispute with Villani, Inc. regarding the strategic shift. Dermata reported a net loss of $7.6 million for fiscal 2025 and held $7.5 million in cash at year-end, with strong liquidity ratios. The company announced a private placement valued at up to $12.4 million in December 2025. Dermata operates in a competitive skincare market with risks including regulatory challenges, competition, supply chain dependencies, and operational execution.

Oramed Pharmaceuticals Inc. develops orally digestible pharmaceutical products, with a focus on oral insulin delivery. The company relies on strategic partnerships and joint ventures for development, commercialization, and marketing, lacking its own large-scale manufacturing and sales infrastructure. It has invested in clinical-stage oncology company Alpha Tau and transferred POD technology to Lifeward, gaining significant equity stakes. Oramed reported net income and revenues for fiscal 2025, supported by strong liquidity. The company faces industry competition, regulatory hurdles, and operational risks including personnel retention and currency exposure. It also invests in real estate assets, adding market and liquidity risk exposure.